Beijing Hotgen Biotech Co., Ltd. (688068.SH) has announced that its controlling subsidiary, Beijing Shunjing Biopharmaceutical Technology Co., Ltd. (Shunjing Pharma), recently received a certificate from the Beijing Municipal Bureau of Economy and Information Technology. Shunjing Pharma has been recognized as a "Specialized, Refined, Unique, and Innovative" Small and Medium-sized Enterprise (SME) in Beijing, with the certification valid from April 2026 to April 2029.

The acquisition of this certification acknowledges Shunjing Pharma's technical expertise, innovation capabilities, and overall strength in the field of innovative biopharmaceuticals. This recognition is expected to enhance the core competitiveness and brand influence of both the parent company and its subsidiary. It will also contribute to the development of sustained innovation capacity and mechanisms, positively impacting and promoting the company's operational growth.